Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals Digital Hospital

KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions

Fineline Cube Aug 15, 2022

Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a...

Company Drug

Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China

Fineline Cube Aug 15, 2022

China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...

Company Deals

Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development

Fineline Cube Aug 15, 2022

Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an...

Company Drug

Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study

Fineline Cube Aug 15, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Company Drug

Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer

Fineline Cube Aug 15, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...

Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Fineline Cube Aug 12, 2022

Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...

R&D

Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients

Fineline Cube Aug 12, 2022

A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted...

Company Deals

Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem

Fineline Cube Aug 12, 2022

Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...

Company Deals

Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech

Fineline Cube Aug 12, 2022

Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...

Company Deals

WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production

Fineline Cube Aug 12, 2022

WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...

Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Company Drug

Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer

Fineline Cube Aug 11, 2022

Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...

Deals Hospital

ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit

Fineline Cube Aug 11, 2022

ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare...

Company Deals Legal / IP Policy / Regulatory

Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center

Fineline Cube Aug 11, 2022

The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...

Company Deals

United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion

Fineline Cube Aug 11, 2022

Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...

Company Medical Device

Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center

Fineline Cube Aug 11, 2022

US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...

Posts pagination

1 … 660 661 662 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.